Beltran Lab

You are here

Publications

Found 69 results
2018
Chedgy ECp, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J et al..  2018.  Biallelic tumor suppressor loss and DNA repair defects in de novo small cell prostate cancer.. J Pathol.
Davies AH, Beltran H, Zoubeidi A.  2018.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.. Nat Rev Urol.
Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V et al..  2018.  Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.. Eur Urol.
Ramnarine VRohan, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M et al..  2018.  The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.. Gigascience.
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, G Han C, Coleman I et al..  2018.  The long tail of oncogenic drivers in prostate cancer.. Nat Genet. 50(5):645-651.
Puca L, Vlachostergios PJ, Beltran H.  2018.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.. Cold Spring Harb Perspect Med.
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2018.  A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.. Clin Cancer Res.
2017
Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y et al..  2017.  Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.. Cancer Cell. 32(6):792-806.e7.
Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2017.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer.
Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA et al..  2017.  A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.. Cold Spring Harb Mol Case Stud. 3(5)
Beltran H, Wyatt AW, Chedgy E, Donoghue A, Annala M, Warner E, Beja K, Sigouros M, Mo F, Fazli L et al..  2017.  Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.. Clin Cancer Res.
Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KMun, Angeles A, Johnson F et al..  2017.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.. Cancer Discov. 7(1):54-71.
Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017
Sailer V, Pauli C, Merzier EC, Mosquera JMiguel, Beltran H, Rubin MA, Rao RA.  2017.  On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.. Anticancer Res. 37(4):1569-1573.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.. Cancer Discov.
Sternberg CN, Beltran H.  2017.  Prostate cancer in 2016: Improved outcomes and precision medicine come within reach.. Nat Rev Urol. 14(2):71-72.
Ku SYu, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez ECortes, Wang J et al..  2017.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.. Science. 355(6320):78-83.
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.
Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang Y et al..  2017.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.. Eur Urol. 71(1):68-78.
O'Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, Simon J, Romesser PB, Leach B, Han T et al..  2017.  Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer.. Nat Biotechnol. 35(6):577-582.